Valuation : United Therapeutics Corporation

Market Cap 21.99B 18.98B 17.88B 16.31B 30.44B 2,088B 30.69B 212B 82.1B 1,062B 82.57B 80.77B 3,494B P/E 2026 *
18.9x
P/E 2027 * 17.1x
Enterprise Value 19.02B 16.42B 15.46B 14.11B 26.33B 1,806B 26.54B 183B 71B 919B 71.41B 69.85B 3,021B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 5.28x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
09-02 United Therapeutics Insider Sold Shares Worth $4,883,839, According to a Recent SEC Filing MT
09-02 United Therapeutics Corporation Announces Fda Acceptance of Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis CI
09-02 United Therapeutics Says FDA Accepts Supplemental Filing for Nebulized Tyvaso in IPF MT
09-01 United Therapeutics Insider Sold Shares Worth $4,855,312, According to a Recent SEC Filing MT
08-28 United Therapeutics Presents Data from Advance Outcomes, Teton, Artisan, and Phinder Studies At European Society of Cardiology Congress 2026 and European Respiratory Society International Congress 2026 CI
08-25 United Therapeutics Insider Sold Shares Worth $4,863,730, According to a Recent SEC Filing MT
08-24 United Therapeutics Says FDA Accepted Application for Pulmonary Arterial Hypertension Treatment MT
08-24 United Therapeutics Corporation Announces FDA Filing Acceptance Of New Drug Application For Ralinepag To Treat Pulmonary Arterial Hypertension CI
08-21 United Therapeutics Insider Sold Shares Worth $4,342,079, According to a Recent SEC Filing MT
08-21 United Therapeutics Insider Sold Shares Worth $4,949,717, According to a Recent SEC Filing MT
08-17 United Therapeutics Insider Sold Shares Worth $4,739,664, According to a Recent SEC Filing MT
08-17 United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso MT
08-17 United Therapeutics Corporation Completes Enrollment Of TETON-PPF Study Of Inhaled Treprostinil For Progressive Pulmonary Fibrosis CI
1 day-4.03%
1 week-5.11%
Current month-3.60%
1 month-4.96%
3 months-9.66%
6 months-2.36%
Current year+0.98%
1 week 477.01
Extreme 477.01
531.76
1 month 477.01
Extreme 477.01
541.03
Current year 455.63
Extreme 455.63
609.35
1 year 375.61
Extreme 375.61
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 26/06/1996
President 54 26/06/2016
Director of Finance/CFO 58 13/03/2015
Director TitleAgeSince
Director/Board Member 78 01/01/2002
Chairman 71 26/06/1996
Director/Board Member 92 01/01/2002
Date Insider Type Main position Quantity % Market Cap. Importance
8/28/26 A Exercice

Chief Executive Officer

28,500 0.0671%
8/27/26 A Exercice

Chief Executive Officer

28,500 0.0671%
8/26/26 A Exercice

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-4.03%-5.11%+61.45%+115.75% 21.99B
+0.01%-5.96%+58.36%+108.23% 1,034B
+1.48%+0.76%+55.34%+71.49% 654B
+0.67%-1.53%+24.39%+76.60% 459B
+0.49%-6.58%+34.20%+34.59% 343B
+0.27%+2.32%+29.33%+46.97% 307B
+0.12%-4.01%+1.06%+11.93% 251B
+1.08%+0.14%+53.92%+72.51% 237B
+2.64%-2.00%-17.38%-53.64% 202B
-0.21%+0.56%+32.43%+95.19% 186B
Average +0.01%-2.70%+33.31%+57.96% 369.36B
Weighted average by Cap. +0.24%-3.30%+39.35%+67.60%

Financials

2026 *2027 *
Net sales 3.14B 2.71B 2.55B 2.33B 4.35B 298B 4.38B 30.23B 11.72B 152B 11.79B 11.53B 499B 3.44B 2.97B 2.8B 2.55B 4.76B 327B 4.8B 33.14B 12.85B 166B 12.92B 12.64B 547B
Net income 1.2B 1.03B 974M 888M 1.66B 114B 1.67B 11.53B 4.47B 57.85B 4.5B 4.4B 190B 1.32B 1.14B 1.07B 977M 1.82B 125B 1.84B 12.69B 4.92B 63.65B 4.95B 4.84B 209B
Net Debt -2.97B -2.57B -2.42B -2.21B -4.12B -282B -4.15B -28.62B -11.1B -144B -11.16B -10.92B -472B -3.81B -3.29B -3.09B -2.82B -5.27B -361B -5.31B -36.65B -14.21B -184B -14.29B -13.98B -605B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
02/09/26 $492.02 -4.03% 1,403,732
01/09/26 $512.70 +0.45% 478,996
31/08/26 $510.38 -0.99% 538,523
28/08/26 $515.46 -2.36% 266,869
27/08/26 $527.91 +2.17% 391,005
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
512.70USD
Average target price
664.33USD
Spread / Average Target
+29.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock